Attention-Deficit Hyperactivity Disorder

The US Food and Drug Administration has approved a new generic option for the treatment of attention-deficit/hyperactivity disorder.

Adherence to a Mediterranean Diet (MD) could be related to lower risk of attention-deficit/hyperactivity disorder (ADHD), according to a recent study.

The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.

A new study evaluated the relationship between epilepsy and symptoms of ADHD, as well as how those symptoms affect patients' quality of life.